180 - Season 12 Recap & Closing the Journey (S12E15)

Welcome to this special edition of the Deep Dive.
You know how we do it, take complex topics, unpack
the key info and give you the insights. But today,
we're doing something a bit different. Instead
of a brand new stack of sources, we're actually,
well, looking back. Yeah, a recap. Exactly, a
recap of season 12, our whole journey through
the frankly fascinating world of drug development
and all the fields connected to it. It's been
quite a ride, hasn't it? We really got into everything
from the very beginnings in preclinical research,
all the way through clinical trials, the regulatory
side of things, and even some of the cutting
edge tech that's changing the game. It really
has been a journey, just trying to wrap our heads
around how these potential medicines go from
a lab concept to actually helping people. So
today the mission is kind of to pull together
the main takeaways, connect some dots, and maybe,
just maybe, peek at what's coming next. Sounds
good. Where should we start? Back at the beginning.
Let's do it. Back to the foundation, preclinical
development. OK. So preclinical studies. These
are absolutely essential first steps. You're
basically trying to see if a compound looks safe
enough and if it might possibly work in humans.
Before anyone actually takes it. Precisely. It's
all about building that initial understanding
how the drug interacts with biological systems
in a controlled setting. And a huge part of that,
as we learned, is using animal models. But picking
the right model isn't simple, is it? No, not
at all. That's a key point. Drug targets can
be surprisingly different between species. Right.
We talked about serotonin receptors, for instance,
the differences between humans, rats, mice. They
might seem small, but they can mean a drug works
differently. So what you see in a rat doesn't
automatically mean it'll happen in a person.
Exactly. It highlights this ongoing challenge
of finding animal models that are truly predictive.
It's a big reason why preclinical efficacy can
be such a stumbling block. And then there's ADME.
That came up a lot. Oh, yes, ADME. Absorption,
distribution, metabolism, excretion. Understanding
these pharmacokinetic properties and understanding
them early, it's vital. Why so early? Well, it
helps you avoid really expensive surprises later
on. We looked at verinostat, remember? Understanding
how it's metabolized in rats and dogs gives you
crucial clues about how it might behave in humans.
It helps with figuring out dosage, potential
interactions, that kind of thing. Precisely.
And it's not just whole animals. We also have
the in vitro studies. Using cells, biochemical
assays. Right. These are critical for that initial
screening. You have maybe thousands of compounds
and these assays help you find the hits, the
ones showing some activity against your target.
So you can narrow things down before the more
complex animal studies. Exactly. It's a funneling
process. And underpinning all this early work,
good laboratory practices, GLP. GLP, yeah. Mandated
by regulations like CFR Title 21, Part 58. It's
basically the quality control system for this
non -clinical work. It ensures the data is reliable.
It's the bedrock of trust, really. Without these
standardized procedures, meticulous records,
the whole foundation of drug safety assessment
would be shaky. OK, so let's say our compound
looks promising and preclinical, passes GLP,
then it moves into clinical trials. We spent
a good chunk of time here. We certainly did.
And we broke down the different phases, right,
each with its own distinct goal. Phase one, primarily
about safety. figuring out dosage. Exactly. Safety
and tolerability usually in a small group of
healthy volunteers or sometimes patients. Then
phase two starts looking more at efficacy. Does
it actually work and what are the side effects
in a slightly larger group? Yep and then phase
three. That's the big one. Large scale trials,
often comparing to existing treatments or placebo,
really trying to confirm efficacy and monitor
safety long term in the kind of population who
would actually use the drug. What really struck
me was how trial designs are evolving. They're
not always so rigid anymore. That's a really
important trend. The move towards adaptive design.
Meaning? Meaning the trial can be modified. in
pre -planned ways, based on the data coming in,
maybe you adjust the dose, maybe you focus on
a subgroup that seems to be responding better.
More flexible, more efficient, maybe. Potentially,
yes. It can help get clearer answers faster than
sticking to a completely fixed plan from day
one. And we also saw biomarkers playing a bigger
role, especially in cancer trials. Huge role.
biomarkers, these measurable indicators can help
you select patients who are more likely to benefit
from a specific drug. So you're enriching the
trial population. Right, which can make it easier
to see if the drug is actually working in those
who stand the best chance of responding, increases
the study's power. Another thing that came up
repeatedly was diversity in phase three. Absolutely
critical. If your trial only includes a narrow
group, how do you know the drug will work safely
and effectively in the you know, diverse real
-world population. Differences in genetics, lifestyle,
all that can matter. It really can. So ensuring
diversity is paramount for generalizability,
making sure the results actually apply broadly.
And when we took phase three trials, we got into
some key concepts for understanding the results.
Endpoints. Right, endpoints. The specific outcomes
you're measuring. Primary endpoint is the main
one, then you have secondary ones. And the statistical
hypotheses, like, are you trying to show the
new drug is better than something else? That's
superiority. Yeah. Or sometimes you just need
to show it's not worse than an existing standard.
Non -inferiority. Exactly. And pulling it all
together is the protocol. That's the detailed
rule book for the entire trial. Everything has
to be defined upfront. Sample size, too. Getting
that right seems crucial. Oh, definitely. Too
small. And you might miss a real effect, not
enough statistical power. We even touched on
sample size re -estimation. Adjusting based on
early results? Sometimes, yes, if it's pre -specified
in the plan. It helps ensure the trial remains
adequately powered. And watching over all of
this, the regulatory guidelines, FDA, ICH. Very
rigorous oversight. They set the standards for
everything, ethical conduct, patient safety,
data integrity, even things like electronic records
and signatures. That was CFR, Title 21, Part
11, right? That's the one. ensuring data is secure
and trustworthy. We also talked about surrogate
endpoints, using things like lab values instead
of, say, survival. Yes, surrogate endpoints can
sometimes speed things up, give earlier indications.
But, and this is a big but, the link has to be
really strong. The surrogate has to reliably
predict the actual clinical benefit for the patient.
Precisely. Otherwise, you risk approving a drug
based on something that doesn't truly matter
to patient's health. And what about those really
small trials for rare diseases, maybe? Yeah,
those present unique challenges. You simply can't
recruit thousands of patients. So you have to
be extra careful interpreting the results. Absolutely.
Small trials can provide valuable evidence, but
you need to be very aware of the limitations
the assumptions made on how strong the conclusions
really are. OK, shifting gears slightly. The
regulatory landscape itself, the FDA's role as
the main gatekeeper in the U .S. Gatekeeper is
the good word. They oversee the whole process,
ensuring drugs meet high standards for safety
and efficacy before they reach the public and
even after. And specific guidelines like for
bioavailability and bioequivalence studies are
fundamental. Totally. Bioavailability tells you
how much drug gets into a bloodstream. Bioequivalence
shows, usually for generics, that they perform
the same way as the original brand. ensures consistency.
And we can't forget the ICH, the International
Conference on Harmonization. Right. Their work
is vital for aligning technical requirements
across different regions, Europe, Japan, the
U .S. Makes it easier for companies developing
drugs globally, avoids redundant testing. Exactly.
Streamlines the process, ultimately helps get
medicines to patients faster worldwide. There
are also special regulatory pathways like orphan
drug designation. Yeah, that's under CFR Title
21 Part 316. It provides incentives, tax credits,
market exclusivity to encourage companies to
develop drugs for rare diseases. Diseases that
might otherwise be neglected because the patient
population is small. Correct. Addressing critical
unmet needs. And the oversight doesn't stop at
approval, right? Post -marketing surveillance.
Absolutely essential. Monitoring safety once
the drug is out in the real world is crucial.
Regulations, like parts of CFR Title 21 Part
202, require prompt reporting of new safety issues.
Keeping patients safe long term. That's the goal.
Before a company even submits their big application,
the NDA, they often talk to the FDA first. pre
-NDA meetings. Highly recommended. It's a chance
to get feedback, make sure the data package is
looking good, that it addresses what the FDA
expects to see, can really smooth out the review
later. And then the main event, the NDA or BLA
submission and review. Right. The company submits
this massive package of data. The FDA first decides
if it's complete enough to even review, that's
the 60 -day filing decision. And then the actual
review timeline kicks in under PDUFA. Yep. PDUFA,
the Prescription Drug User Fee Act, sets target
dates. Usually a standard review maybe 10 months
or a priority review, maybe six months for drugs
that could be significant advances. Trying to
speed up access for important new medicines.
That's the idea. OK. Besides the core process,
season 12 also dove into a lot of exciting new
technologies and innovations that felt like looking
into the future. It really did. And AI and machine
learning kept coming up, didn't they? Yeah. In
drug discovery, finding targets, analyzing complex
data. It's rapidly finding applications across
the board, identifying potential drug hits, designing
molecules, even optimizing clinical trials. Huge
potential there. And those ADME -enabling technologies
getting better at designing drugs with the right
pharmacokinetic properties from the start. Crucial
for reducing late -stage failures. If you can
build in good ADME properties early, the drug
has a much better chance of actually working
in the body. We also looked at innovative delivery
systems, nanoparticles, dendrimers. Really clever
stuff. The goal is often targeted delivery, getting
the drug right where it needs to go, minimizing
side effects elsewhere. Like those PAM dendrimers
for getting drugs through the skin. Exactly.
Or nanoparticles designed to accumulate in tumors.
Lots of exciting work in that area. And IVIVC
and vitro in vivo correlations, linking lab tests
to real -world performance. Yeah, that can be
a powerful tool. If you can establish a reliable
IVIVC, your lab dissolution test can actually
predict how the drug will release in a person.
Like with those pseudoephedrine auris tablets
we discussed. Good example. Helps ensure batch
-to -batch consistency translates to consistent
performance in patients. We also touched on more
fundamental chemistry aspects like understanding
molecular interactions, SAR studies. Structure
activity relationships. Core medicinal chemistry.
How does changing the molecule's structure affect
its biological activity? You systematically tweak
things to optimize potency selectivity. Designing
better drugs atom by atom, almost. That's the
art and science of it, yeah. Even something seemingly
simple like... polymorphism, how the drug crystallizes
matters. Oh, hugely. Different crystal forms,
polymorphs can have different... solubility,
stability, which directly impacts how well the
drug gets absorbed. You have to understand and
control it. On the data analysis front, dynamic
mode decomposition, DMD, that sounded pretty
advanced. It's a sophisticated way to pull out
key dynamic patterns from really complex data
sets, like you might get from biological systems,
finding underlying trends you might otherwise
miss. And in manufacturing, process chemistry
is getting smarter too. Definitely. Things like
transition metal catalyzed couplings, flow chemistry.
These allow for making complex drug molecules
more efficiently, cleanly, scalably. We saw that
example of making those perfluoroalkylpyridines.
Right, using novel cyclization reactions. It
showcases how advanced synthesis methods enable
access to new types of potentially useful molecules.
And wrapping up the tech side, quality by design,
QBD. A very important philosophy. Instead of
just testing quality at the end, you build it
in from the start. understanding your process,
controlling the critical factors. To ensure consistent
quality product every time. Exactly. It's a proactive,
science -driven approach. So as we kind of pull
back and look at this whole season, this whole
field, what are your big picture reflections?
Well, my main takeaway is just the sheer complexity
and how incredibly interdisciplinary it is. You
need biologists, chemists, statisticians, clinicians,
engineers, regulatory experts. all working together.
It's definitely not a solo effort. Not even close.
And the other thing is it just never stops changing.
Always evolving, isn't it? New science, new tech.
Absolutely. Our understanding of disease keeps
getting deeper. Technology offers new tools.
Regulatory approaches adapt. It's constantly
moving forward. Looking ahead then, what excites
you most? What innovations do you think will
really shape the next, say, decade? Oh wow. Well,
I think AI and machine learning will become even
more integrated, maybe truly personalized medicine
based on deep data analysis. Tailoring treatments
more precisely? I think so. Also, better models,
maybe complex organoids or human -on -a -chip
tech that better predict human responses than
current methods. Reducing reliance on animal
models, perhaps? That's certainly a goal. and
continued advances in targeted delivery, maybe
RNA therapeutics becoming even more mainstream,
and definitely more efficient greener manufacturing.
It all aims towards getting better, safer medicines
to patients faster. It really has been an incredibly
informative season. Digging into all these pieces,
it gives you a real appreciation for the effort
involved. It really does. The dedication required
to navigate this complex path is immense. It's
been a pleasure recapping it all. Yeah, it really
puts the whole journey from lab bench to bedside
into perspective. Thank you for joining us for
this special deep dive, this look back at season
12. I hope connecting these dots, preclinical,
clinical, regulatory tech has been valuable.
Me too. Seeing how they all fit together, how
they influence each other. That's key to understanding
the whole ecosystem, isn't it? Absolutely. And
now as we finish our reflection on the season,
here's something to think about. We've talked
a lot about the rapid pace of innovation. So
what truly transformative changes might we realistically
expect in drug development over the next 10 years?
And maybe more importantly, how will those changes
actually impact the lives of patients? What difference
will it make day to day? That's a great question
to ponder. And of course, if you want to revisit
any specific area we touched on today in more
detail, All the individual deep dives from season
12 are right there in our archives. Definitely
check those out. Thanks again for diving deep
with us today. We look forward to our next learning
journey together. Until next time.